Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2017 (2017), Article ID 2560191, 8 pages
https://doi.org/10.1155/2017/2560191
Research Article

Application of the AMLprofiler Diagnostic Microarray in the South African Setting

1Institute for Cellular and Molecular Medicine, Department of Immunology, Faculty of Health Sciences, and SAMRC Extramural Unit for Stem Cell Research and Therapy, University of Pretoria, Pretoria, South Africa
2Department of Haematology, Faculty of Health Sciences, University of Pretoria and National Health Laboratory Services, Pretoria, South Africa

Correspondence should be addressed to M. S. Pepper; az.ca.pu@reppep.leahcim

Received 21 May 2017; Revised 9 August 2017; Accepted 12 October 2017; Published 7 November 2017

Academic Editor: Linda Sommese

Copyright © 2017 S. S. Kappala et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Walker and G. Marcucci, “Molecular prognostic factors in cytogenetically normal acute myeloid leukemia,” Expert Review of Hematology, vol. 5, no. 5, pp. 547–558, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. S. J. McKenna, “Leukemia,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, vol. 89, no. 2, pp. 137–139, 2000. View at Publisher · View at Google Scholar
  3. H. Döhner, E. H. Estey, S. Amadori et al., “Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet,” Blood, vol. 115, no. 3, pp. 453–474, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. J. W. Vardiman, J. Thiele, D. A. Arber et al., “The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes,” Blood, vol. 114, no. 5, pp. 937–951, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Grimwade, R. K. Hills, A. V. Moorman et al., “Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials,” Blood, vol. 116, no. 3, pp. 354–365, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. R. S. Ohgami, L. Ma, J. D. Merker et al., “Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations,” Modern Pathology, vol. 28, no. 5, pp. 706–714, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Döhner, E. Estey, D. Grimwade et al., “Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel,” Blood, vol. 129, no. 4, pp. 424–447, 2017. View at Publisher · View at Google Scholar
  8. S. Schwind, G. Marcucci, J. Kohlschmidt et al., “Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia,” Blood, vol. 118, no. 15, pp. 4188–4198, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Langer, M. D. Radmacher, A. S. Ruppert et al., “High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study,” Blood, vol. 111, no. 11, pp. 5371–5379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Brand, M. H. van Vliet, L. de Best et al., “A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC,” Experimental Hematology & Oncology, vol. 2, no. 1, p. 7, 2013. View at Publisher · View at Google Scholar
  11. J. F. Nomdedéu, E. Puigdecanet, E. Bussaglia et al., “Feasibility of the AML profiler (Skyline™ Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach,” Hematological Oncology, 2016. View at Publisher · View at Google Scholar
  12. K. Tawana, A. Rio-Machin, C. Preudhomme, and J. Fitzgibbon, “Familial CEBPA-mutated acute myeloid leukemia,” Seminars in Hematology, vol. 54, no. 2, pp. 87–93, 2017. View at Publisher · View at Google Scholar
  13. S. Schnittger, C. Schoch, W. Kern et al., “Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype,” Blood, vol. 106, no. 12, pp. 3733–3739, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. R. C. Marshall, A. Tlagadi, M. Bronze et al., “Lower frequency of NPM1 and FLT3-ITD mutations in a South African adult de novo AML cohort,” International Journal of Laboratory Hematology, vol. 36, no. 6, pp. 656–664, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. W. C. Chou, J. L. Tang, L. I. Lin et al., “Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution,” Cancer Research, vol. 66, no. 6, pp. 3310–3316, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Ahmad, S. Mandava, and B. R. Das, “Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population,” Hematological Oncology, vol. 27, no. 2, pp. 90–97, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Lugthart, E. van Drunen, Y. van Norden et al., “High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated,” Blood, vol. 111, no. 8, pp. 4329–4337, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. S. J. Xiao, J. Z. Shen, J. L. Huang, and H. Y. Fu, “Prognostic significance of the BAALC gene expression in adult patients with acute myeloid leukemia: a meta-analysis,” Molecular and Clinical Oncology, vol. 3, no. 4, pp. 880–888, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. A. M. Ilyas, S. Ahmad, M. Faheem et al., “Next generation sequencing of acute myeloid leukemia: influencing prognosis,” BMC Genomics, vol. 16, Supplement 1, p. S5, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Luthra, K. P. Patel, N. G. Reddy et al., “Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using Miseq: applicability for diagnostics and disease monitoring,” Haematologica, vol. 99, no. 3, pp. 465–473, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Delaunay, N. Vey, T. Leblanc et al., “Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup,” Blood, vol. 102, no. 2, pp. 462–469, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Billstrom, T. Ahlgren, A. N. Bekassy et al., “Acute myeloid leukemia with inv(16)(p13q22): involvement of cervical lymph nodes and tonsils is common and may be a negative prognostic sign,” American Journal of Hematology, vol. 71, no. 1, pp. 15–19, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Mrozek, N. A. Heerema, and C. D. Bloomfield, “Cytogenetics in acute leukemia,” Blood Reviews, vol. 18, no. 2, pp. 115–136, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. J. C. Byrd, K. Mrózek, R. K. Dodge et al., “Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461),” Blood, vol. 100, no. 13, pp. 4325–4336, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Schwind, C. G. Edwards, D. Nicolet et al., “inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations,” Blood, vol. 121, no. 2, pp. 385–391, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Mrozek and C. D. Bloomfield, “Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia,” Journal of the National Cancer Institute Monographs, vol. 2008, no. 39, pp. 52–57, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Grimwade, “The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia,” Best Practice & Research Clinical Haematology, vol. 14, no. 3, pp. 497–529, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. P. J. Valk, R. G. Verhaak, M. A. Beijen et al., “Prognostically useful gene-expression profiles in acute myeloid leukemia,” The New England Journal of Medicine, vol. 350, no. 16, pp. 1617–1628, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Cheng, Y. Wang, H. Wang et al., “Cytogenetic profile of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China,” Leukemia, vol. 23, no. 10, pp. 1801–1806, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. D. A. Arber, A. S. Stein, N. H. Carter, D. Ikle, S. J. Forman, and M. L. Slovak, “Prognostic impact of acute myeloid leukemia classification: importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival,” American Journal of Clinical Pathology, vol. 119, no. 5, pp. 672–680, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. M. L. Chauffaille, M. S. Figueiredo, R. Beltrani, S. V. Antunes, M. Yamamoto, and J. Kerbauy, “Acute promyelocytic leukemia: the study of t(15;17) translocation by fluorescent in situ hybridization, reverse transcriptase-polymerase chain reaction and cytogenetic techniques,” Brazilian Journal of Medical and Biological Research, vol. 34, no. 6, pp. 735–743, 2001. View at Publisher · View at Google Scholar
  32. K. Mrozek, “Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype,” Seminars in Oncology, vol. 35, no. 4, pp. 365–377, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Y. Meng, P. J. Noor, A. Ismail, M. F. Ahid, and Z. Zakaria, “Cytogenetic profile of de novo acute myeloid leukemia patients in Malaysia,” International Journal of Biomedical Sciences, vol. 9, no. 1, pp. 26–32, 2013. View at Google Scholar
  34. T. Pabst, B. U. Mueller, P. Zhang et al., “Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia,” Nature Genetics, vol. 27, no. 3, pp. 263–270, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. A. F. Gombart, W. K. Hofmann, S. Kawano et al., “Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein α in myelodysplastic syndromes and acute myeloid leukemias,” Blood, vol. 99, no. 4, pp. 1332–1340, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Preudhomme, C. Sagot, N. Boissel et al., “Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the acute leukemia French association (ALFA),” Blood, vol. 100, no. 8, pp. 2717–2723, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Snaddon, M. L. Smith, M. Neat et al., “Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2,” Genes, Chromosomes and Cancer, vol. 37, no. 1, pp. 72–78, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Barjesteh van Waalwijk van Doorn-Khosrovani, C. Erpelinck, J. Meijer et al., “Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML,” The Hematology Journal, vol. 4, no. 1, pp. 31–40, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Fröhling and H. Döhner, “Disruption of C/EBPα function in acute myeloid leukemia,” The New England Journal of Medicine, vol. 351, no. 23, pp. 2370–2372, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Nerlov, “C/EBPα mutations in acute myeloid leukaemias,” Nature Reviews Cancer, vol. 4, no. 5, pp. 394–400, 2004. View at Publisher · View at Google Scholar
  41. M. Bienz, M. Ludwig, E. O. Leibundgut et al., “Risk assessment in patients with acute myeloid leukemia and a normal karyotype,” Clinical Cancer Research, vol. 11, no. 4, pp. 1416–1424, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. B. Falini, I. Nicoletti, M. F. Martelli, and C. Mecucci, “Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features,” Blood, vol. 109, no. 3, pp. 874–885, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Thiede, S. Koch, E. Creutzig et al., “Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML),” Blood, vol. 107, no. 10, pp. 4011–4020, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Cazzaniga, M. G. Dell'Oro, C. Mecucci et al., “Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype,” Blood, vol. 106, no. 4, pp. 1419–1422, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. R. G. Verhaak, C. S. Goudswaard, W. van Putten et al., “Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance,” Blood, vol. 106, no. 12, pp. 3747–3754, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. P. Brown, E. McIntyre, R. Rau et al., “The incidence and clinical significance of nucleophosmin mutations in childhood AML,” Blood, vol. 110, no. 3, pp. 979–985, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. G. R. Ruan, J. L. Li, Y. Z. Qin et al., “Nucleophosmin mutations in Chinese adults with acute myelogenous leukemia,” Annals of Hematology, vol. 88, no. 2, pp. 159–166, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Gröschel, S. Lugthart, R. F. Schlenk et al., “High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities,” Journal of Clinical Oncology, vol. 28, no. 12, pp. 2101–2107, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Glass, M. Wilson, R. Gonzalez, Y. Zhang, and A. S. Perkins, “The role of EVI1 in myeloid malignancies,” Blood Cells, Molecules & Diseases, vol. 53, no. 1-2, pp. 67–76, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Barjesteh van Waalwijk van Doorn-Khosrovani, C. Erpelinck, W. L. van Putten et al., “High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients,” Blood, vol. 101, no. 3, pp. 837–845, 2003. View at Publisher · View at Google Scholar · View at Scopus